These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3917530)

  • 41. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Registry of DNA polymorphisms within or close to the human factor VIII and factor IX genes. For the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
    Peake I
    Thromb Haemost; 1992 Feb; 67(2):277-80. PubMed ID: 1352417
    [No Abstract]   [Full Text] [Related]  

  • 43. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of individual factor VIII or IX level for the correction of thrombin generation in haemophilic patients.
    Chelle P; Montmartin A; Piot M; Ardillon L; Wibaut B; Frotscher B; Cournil M; Morin C; Tardy-Poncet B
    Haemophilia; 2018 Nov; 24(6):995-1001. PubMed ID: 29957846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 47. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 48. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes.
    Begbie M; Mueller C; Lillicrap D
    DNA Cell Biol; 1999 Feb; 18(2):165-73. PubMed ID: 10073576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Measurements of the activity of the coagulation factors VIII:C, IX,XI, and XII in cats].
    Mischke R; Deniz A; Nolte I
    Zentralbl Veterinarmed A; 1995 Oct; 42(8):513-20. PubMed ID: 8592897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factor X in freeze-dried factor- VIII reference plasma.
    Bangham DR; Robertson I; Gurd LJ; Brozović M
    Br J Haematol; 1971 Aug; 21(2):201-8. PubMed ID: 5559982
    [No Abstract]   [Full Text] [Related]  

  • 53. [LIFE SPAN OF FACTORS VIII AND IX (ANTIHEMOPHILIC FACTORS A AND B) INJECTED INTO HEMOPHILICS].
    MENACHE D; JOSSO F
    Hemostase; 1963; 3():139-48. PubMed ID: 14054335
    [No Abstract]   [Full Text] [Related]  

  • 54. Cryoprecipitated factor VIII concentrate.
    Pool JG
    Thromb Diath Haemorrh Suppl; 1968; 35():35-40. PubMed ID: 5317363
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [In vitro study of different factor VIII concentrates. Biochemical and structural characteristics of factor VIII (author's transl)].
    Massot M; Vidal A; Más J; Laguna V; Vilanova X
    Sangre (Barc); 1982; 27(1):39-52. PubMed ID: 6808678
    [No Abstract]   [Full Text] [Related]  

  • 58. Factor VIII and factor IX concentrates in surgery in hemophilia.
    Wolman IJ
    JAMA; 1971 Feb; 215(8):1328. PubMed ID: 5107574
    [No Abstract]   [Full Text] [Related]  

  • 59. The interaction between factor VIII clotting antigen (VIIICAg) and phospholipid.
    Yoshioka A; Peake IR; Furlong BL; Furlong RA; Giddings JC; Bloom AL
    Br J Haematol; 1983 Sep; 55(1):27-36. PubMed ID: 6411112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factor VIII concentrate: a comparison of manufacturers' assays and users' assays. Report of a survey carried out on behalf of the ICTH subcommittee on Factor VIII activities.
    Rizza CR
    Thromb Haemost; 1983 Oct; 50(3):753-4. PubMed ID: 6417822
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.